• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    anti-infectious lubricant for medical devices and methods for preparing it. A lubricant antiseptic coating material that contains various solvents to achieve mutual miscibility and provide a generally homogeneous product. A coating material is provided which has a lubricating agent and a solvent for the antipathogen and a solvent for dissolving it. The coating further includes a lubricating agent and a solvent for dissolving it. thus, the coating material contains antiseptic and lubricating properties suitable for softening on a desired surface to maintain or inhibit the growth of pathogens known to cause catheter-related bloodstream infections.
    公开号:BR112012005874B1
    申请号:R112012005874
    申请日:2010-08-16
    公开日:2018-10-09
    发明作者:Quang Hoang Minh；A Khan Mohammad
    申请人:Becton Dickinson Co；
    IPC主号:
    专利说明:

    (54) Title: ANTIMICROBIAL COMPOSITION, METHOD FOR THE PRODUCTION OF A COMPOSITION
    ANTIMICROBIAL AND INTRAVASCULAR SYSTEM FOR THE PREVENTION OF INFECTIONS IN THE BLOOD CURRENT RELATED TO CATHETERS (73) Holder: BECTON, DICKINSON AND COMPANY, Sociedade Norte Americana. Address: 1, Becton Drive, Franklin Lakes, New Jersey 07417-1880, UNITED STATES OF AMERICA (US) (72) Inventor: MINH QUANG HOANG; MOHAMMAD A. KHAN
    Validity Term: 20 (twenty) years from 8/16/2010, subject to legal conditions
    Issued on: 10/9/2018
    Digitally signed by:
    Liane Elizabeth Caldeira Lage
    Director of Patents, Computer Programs and Topographies of Integrated Circuits
    1/17 “ANTIMICROBIAL COMPOSITION, METHOD FOR THE PRODUCTION OF AN ANTIMICROBIAL COMPOSITION AND INTRAVASCULAR SYSTEM FOR THE PREVENTION OF CATHETER RELATED BLOOD CURRENT INFECTIONS”
    BACKGROUND OF THE INVENTION [001] This disclosure relates generally to lubricating antiseptic coating materials. In particular, this disclosure discusses an antiseptic coating material based on silicone oil that contains various solvents to achieve mutual miscibility of the material components.
    [002] In the fields of medicine and health care, a patient's skin can be perforated in several ways and for a variety of reasons. In one example, a patient's skin is cut with a sharp object, such as a scalpel, for surgical reasons. In another example, a cannula or an intravenous (“IV”) catheter is forced through the patient's skin into an internal space, such as the patient's vasculature. In this example, the cannula or IV catheter can be used to infuse fluid (eg, saline, medication and / or total parenteral nutrition) to the patient, to draw fluids (eg, blood) from the patient and / or to monitor various parameters of the patient's vascular system.
    [003] However, when a patient's skin is punctured, the probability of infection in the patient increases. In fact, it is estimated that each year hundreds of thousands of patients in the United States just develop some form of bloodstream infection that is caused by pathogens that have been transmitted to the patient through or because of an IV catheter or other delivery device. IV access, such as a hypodermic needle. Many of the bacterial pathogens that cause these catheter-related bloodstream infections are common colonizers of the skin or flora that exist on the patient's skin and are believed to enter the patient's body frequently through the catheter insertion site.
    [004] These catheter-related bloodstream infections often cause illness to the patient and, in some cases, death. In addition, due to the fact that
    Petition 870180057384, of 7/3/2018, p. 14/34
    2/17 that some infections are caused by bacterial strains (eg, Methicillin-resistant Staphylococcus aureus (“MRSA”) and Vancomycin-resistant Enterococci (“VRE”)) that are resistant to antibiotics, such infections can be difficult to treat and may increase in prevalence. In addition, due to the fact that patients who have a bloodstream infection may require additional medical treatment, catheter-related bloodstream infections may also be associated with higher medical costs.
    [005] In an attempt to limit bloodstream infections (ie, catheter-related infections) in hospital, outpatient, home care and other health care settings, many have tried to apply various antiseptic coatings to devices and medical equipment. The antiseptic coating is provided as a barrier to prevent the growth or colonization of pathogens commonly associated with infections in the bloodstream. However, such antiseptic coatings are not free from their shortcomings. For example, many of the antipathogenic agents within the coating materials are water soluble and, therefore, are easily washed from medical devices during contact with fluids associated with a patient. In addition, some of the most efficient antipathogenic agents leave a sticky or sticky residue when dried, thus making it difficult to work with the medical device for procedures that require a lubricating interface between the medical device and the patient.
    [006] So, although there are techniques that are used to coat or otherwise treat the surfaces of medical devices to prevent infection, there are still challenges. Consequently, it would be an improvement in the art to improve or even replace current techniques with other techniques.
    BRIEF SUMMARY OF THE INVENTION [007] The present patent application relates to a lubricating antiseptic coating material capable of being applied to an intravascular device to kill or prevent
    Petition 870180057384, of 7/3/2018, p. 15/34
    3/17 growth of a wide range of pathogens. In some embodiments, the antiseptic coating material includes one or more antipathogenic agents selected to kill or inhibit the growth of various pathogens. The antipathogenic agent is generally soluble in at least one of water and a lower alcohol that has no more than two carbon atoms. Consequently, the coating material further includes a solvent for dissolving the antipathogenic agent within the coating material.
    [008] Additional components of the antiseptic coating material include a lubricating agent to ensure a lubricating interface between the coated medical device and the patient. In some embodiments, the lubricating agent is selected from one or more silicone oils. Silicone oils are generally soluble in at least one of a hydrocarbon, a ketone, a halogenated hydrocarbon and higher alcohols that have at least 3 carbon atoms. Consequently, the coating material further includes a solvent for dissolving the lubricating agent within the coating material.
    [009] An important feature of the present invention is the mutual miscibility of the various components of the antiseptic coating material. Thus, in some embodiments of the present invention, various combinations of antipathogenic agents, antipathogenic solvents, lubricating agents and mutually miscible lubricating agent solvents are provided to ensure a homogeneous coating material. In some embodiments, the coating material also includes a polyethoxylated surfactant to further guarantee miscibility of the various components of the coating. In other embodiments, large numbers of solvents are combined to achieve a mutually miscible and homogeneous coating material.
    [010] In some embodiments, the antiseptic coating material is modified to have any suitable characteristic desired to enable the application of the material on a desired surface. For example, in some embodiments the coating material is supplied in a liquid form that is applied to the surface of a medical device by dipping or brushing. In other embodiments, the coating material is supplied
    Petition 870180057384, of 7/3/2018, p. 16/34
    4/17 in at least one of a gel, cream, foam, aerosol or other fluid that has a desired consistency and viscosity.
    [011] The coating material of the present invention can be applied to any desired surface. For example, in some embodiments, the coating material is applied directly to at least one of the external and internal surfaces of an intravascular medical device. In other embodiments, the coating material is applied directly to the patient's skin before drilling or otherwise compromising the skin for a medical procedure.
    DETAILED DESCRIPTION OF THE INVENTION [012] In order to provide a complete understanding of the invention, the following description discusses specific details. The person skilled in the art, however, would understand that the invention can be practiced without using these specific details. In fact, the invention can be modified in any suitable way and can be used in association with any suitable chemical reagent, equipment and technique conventionally used in the industry. Thus, the more detailed description below of the modalities of the invention is not intended to be limiting in scope, but is merely representative of some preferred modalities today. In addition, although the following discussion focuses on the use of the invention in healthcare settings, the antiseptic material can be used in any suitable environment.
    [013] Generally, the present invention relates to a lubricating antiseptic coating material capable of being applied to an intravascular device to kill or prevent the growth of a wide range of pathogens. As used herein, the terms pathogen and pathogens can include any potentially infectious microorganisms, such as bacteria (for example, wavy bacteria, gram-negative bacteria, gram-positive bacteria, aerobic bacteria, anaerobic bacteria, mycobacteria, spirochetes, Staphylococcus epidermis, Staphylococcus aureus, Escherichia coli, Proteus vulgaris, Streptococcus faecalis, Klebsiella, Enterobacter aerogenes, Proteus mirabilis and
    Petition 870180057384, of 07/03/2018, p. 17/34
    5/17 similar), fungi (for example, fungal spores, Aspergillus niger, Aspergillus flavus, Rhizopus nigricans, Cladosporium herbarium, Epidermophyton Floccosum, Trichophyton mentagrophytes, Histoplasma capsulatum and the like), yeast (for example, Cerisia and Candies ), viruses or other potentially dangerous microorganisms.
    [014] A preferred application of the present invention is the application of the antiseptic coating material directly to the external surfaces of an intravascular device, such as an intravenous catheter. In some embodiments, the coating material is applied only to the surfaces of the intravascular device that come into direct contact with the patient. In other embodiments, the coating material is applied to any surface of the intravascular device susceptible to colonization by the pathogen. Thus, when the coated intravascular device is placed on the patient's skin, the antiseptic properties of the coating material kill or prevent the growth of pathogens that can potentially lead to catheter-related bloodstream infection (CRBSI).
    [015] The antiseptic coating material includes several mutually miscible components selected to provide a coating material that is both anti-infectious and lubricating. Generally, all catheters in use for patient care are lubricated with various viscosities of silicone oils. Silicone oils are silicon analogues of carbon-based organic compounds that form relatively long and complex silicon-based molecules instead of carbon. The chains of the silicone oil are formed of alternating siloxane atoms that are replaced by several other species in the tetravalent silicon atoms.
    [016] The embodiments of the present invention contain silicone oils that serve as lubricating agents within the antiseptic material. Silicone oils according to the modalities of the present invention are selected in relation to their lubricating properties and their miscibility within the antiseptic coating material. Besides that,
    Petition 870180057384, of 7/3/2018, p. 18/34
    6/17 silicone oils are selected in relation to their general lack of solubility in water and other fluids associated with a patient, such as blood, sweat, water and urine. Once applied to the surface of an intravascular device, the silicone oil component prevents the coating material from being easily removed from the surface of the device. Thus, the silicone oil preserves the antiseptic properties of the coating, ensuring adhesion between the coating material and the overflow device. Non-limiting examples of silicone oils used in accordance with the present invention include dimethicone, trifluorpropylmethylsiloxane and combinations thereof. One skilled in the art will appreciate that other silicone oils can be used successfully in accordance with the teachings of the present invention.
    [017] An important aspect of the present invention requires that each component of the antiseptic coating material be mutually miscible in order to provide a generally homogeneous coating material. Consequently, the coating material comprises several compatible miscible components, including compatible solvents for dissolving the various components in mutually miscible solutions that are mixed to provide the coating material. Thus, while some components may be soluble in silicone oils, other components may be insoluble and therefore require an additional solvent. In addition, in some embodiments, a solvent is required to enable the silicone oil to dissolve within the coating material.
    [018] For example, in some embodiments, the antiseptic coating material also includes a solvent capable of miscibly dissolving the silicone oil. A desirable silicone oil solvent will generally be compatible or miscible with the other components of the coating material. Suitable solvents can include various hydrocarbons, ketones, halogenated hydrocarbons and alcohols that have at least 3 carbon atoms. Non-limiting examples of silicone oil solvents compatible with and in accordance with the present invention include methyl nonafluorbutyl ether, ethyl ether
    Petition 870180057384, of 7/3/2018, p. 19/34
    7/17 nonafluorbutyl and trans-1,2-dichlorethylene and polyethoxylated surfactants. In some embodiments, the coating material includes a single silicone oil solvent. In other embodiments, the coating material includes a mixture of silicone oil solvents.
    [019] An important component of the antiseptic coating material is an antipathogenic agent selected to kill or prevent the growth of various pathogens. A desirable antipathogenic agent is generally selected based on its ability to inhibit pathogenic activity and to combine miscibility with the other components of the coating material. Non-limiting examples of compatible highly efficient antipathogenic agents include chlorhexidine diacetate, chlorhexidine gluconate, triclosan, benzalkonium chloride, para-chloro-meta-xylenol (PCMX) and other agents known to inhibit bacterial growth.
    [020] The most highly efficient antipathogenic agents are soluble in water or lower alcohols, such as alcohols that have no more than two carbon atoms. However, these agents are generally insoluble in silicone oils, thus making it difficult to dissolve some antipathogenic agents, such as chlorhexidine diacetate and triclosan, in silicone oils. Therefore, in some embodiments of the present invention it is desirable to include within the coating material a solvent capable of miscibly dissolving the antipathogenic agent. Non-limiting examples of compatible antipathogenic solvents include water and lower alcohols, such as methanol and ethanol.
    [021] The antiseptic coating material can include any suitable concentrations of the aforementioned components to provide a mutually miscible anti-infective coating capable of being applied to an intravascular device. Referring now to Table 1, nine formulations of various antiseptic coating materials are shown, in accordance with representative embodiments of the present invention.
    Table 1
    Petition 870180057384, of 7/3/2018, p. 20/34
    8/17
    Ingredients Formulation Numbers (% w / w)
    1 2 3 4 5 6 7 8 9 Nonafluorfluorbu- methyl ether 43.35 29.75 2.64 8.1 45.8 7.3 - ·· tyllic - - - 16.2 - 14.6 - - - Nonafluorofluoroethyl ether 43.35 29.75 2.23 56.7 38.76 51.10 - - - lyric 10.00 30.00 5.13 15.0 12.34 20.0 10.0 13.93 13.85 Trans-1,2-dichlorethylene 3.00 3.00 - 3.00 3.00 3.00 3.00 - - Ethanol, USP 12500 cst silicone - - 89.5 - - - - 85.58 84.08 Dimethylsiloxane and Trifluorflu- - - - - - - 89.8 - - orpropylmethylsiloxane - - - - - - - 0.99 1.09 Hydrochlorofluorfluorocarbon- __ __ __ __ __ __ __ 0.49 grandson 0.30 7.50 0.50 1.00 0.1 4.00 0.20 0.50 0.49
    Cremophor EL ® [022] In some embodiments, the silicone oil added to the coating material is highly concentrated, thus requiring the addition of a relatively small amount. For example, formulations 1, 2 and 4-6 each comprise a highly viscous and concentrated 12,500 cst silicone thus resulting in only 3% of the total weight of the coating material being attributed to the silicone oil. Conversely, formulations 3, 8 and 9 each contain an inferior concentrated mixture of silicone oils with dimethylsiloxane and Trifluorpropylmethylsiloxane thus resulting in approximately 84% to 90% of the total weight of the formulation being attributed to silicone oils. Finally, formulation 7 comprises both highly concentrated 12,500 cSt silicone (3%) and a mixture of silicone oils (89.8%) for a total percentage weight of approximately 93% being attributed to silicone oils.
    [023] Each formulation includes at least one solvent to aid in the solubilization of silicone oil. In some embodiments, various silicone oil solvents are added to the formulation. For example, formulation 7 includes a single halogenated hydrocarbon solvent, while formulations 1-3 and 5 each contain two halogenated hydrocarbon solvents, each solvent or combination of solvents being provided to dissolve their respective silicone oils. Similarly, formulations 4 and 6 contain
    Petition 870180057384, of 07/03/2018, p. 21/34
    9/17 each three halogenated hydrocarbon solvents. In contrast, formulations 8 and 9 do not contain any halogenated hydrocarbon solvents, but instead contain a polyethoxylated surfactant, Cremophor EL ®. For formulations containing non-halogenated solvents, such as formulations 8 and 9, it has been observed that the addition of a small polyethoxylated surfactant increases the miscibility of silicone oils within the coating material. Therefore, in some embodiments of the present invention, the silicone oil solvent must include at least one of a halogenated hydrocarbon solvent and a polyethoxylated surfactant.
    [024] Each formulation includes at least one antipathogenic agent. An antipathogenic agent according to the present invention can include any isolated compound, chemical reagent, reagent, medication, substrate or solution capable of killing or otherwise preventing the growth of a pathogen. In addition, an antipathogenic agent according to the present invention can include any combination of compounds, chemical reagents, reagents, medicaments, substrates or solutions capable of killing or otherwise preventing the growth of a pathogen. Common antipathogenic agents according to various embodiments of the present invention include chlorhexidine diacetate, chlorhexidine gluconate, triclosan, benzalkonium chloride, para-chloro-meta-xylenol (PCMX) and other agents known to inhibit bacterial growth.
    [025] In some embodiments, an antipathogenic agent is selected based on the agent's ability to inhibit a specific pathogen or a class of pathogens. For example, formulations 1 through 8 each contain chlorhexidine diacetate in various concentrations from approximately 0.1% to 7.5% of the total weight of the coating material. Chlorhexidine diacetate is a chemical antiseptic that kills both gram-positive and gram-negative microorganisms. Chlorhexidine diacetate is also commonly used for its bacteriostatic properties. Therefore, formulations 1 through 8 are generally provided for those applications where prevention of bacterial growth is desired. In contrast, formulation 9 includes both antipathogenic agents
    Petition 870180057384, of 7/3/2018, p. 22/34
    10/17 chlorhexidine diacetate and triclosan. Triclosan is a potent antibacterial and antifungal agent with a broad spectrum. Thus, in addition to killing bacterial microorganisms, formulation 9 is also effective against fungal microorganisms, thus making formulation 9 a broader antiseptic coating material.
    [026] As mentioned earlier, some embodiments of the present invention further include a solvent capable of miscibly dissolving the antipathogenic agent. Generally, this antipathogenic solvent is selected to dissolve the antipathogenic agent so that all components within the antiseptic coating material are mutually miscible. The antipathogenic solvent is selected from at least one of water and a lower alcohol containing no more than two carbon atoms. The formulations in Table 1 each contain the ethanol solvent of approximately 5.13% to 30.0% of the total weight of the coating material. The various concentrations of the ethanol solvent were selected based on the concentrations of the other components that are necessary to achieve mutual miscibility.
    [027] In some embodiments, the antiseptic coating material comprises more than one type of alcohol. In such embodiments, the coating material can comprise any suitable number of alcohols, including 2, 3, 4 or more alcohols. In addition, the antipathogenic solvent can comprise any suitable combination of alcohols. In one example, the solvent comprises methanol and ethanol.
    [028] One skilled in the art will consider that the mutual miscibility of the material of the components of the antiseptic coating can be achieved through the use of various solvents and solvent combinations. A person skilled in the art will also consider that some solvents may be included to intentionally increase or decrease the effectiveness of the coating material. For example, in some embodiments, a selected solvent, such as an alcohol, may be included at a higher concentration to further inhibit the growth of a pathogen. In other embodiments, a selected solvent, such as an alcohol, can be combined with an emollient or moisturizer to neutralize irritation
    Petition 870180057384, of 07/03/2018, p. 23/34
    11/17 and skin dryness associated with the solvent.
    [029] As mentioned earlier, in some embodiments the solvent antipathogenic agent comprises water. In such embodiments, water can be supplied to the antiseptic coating material in any suitable aqueous solution, including a diluted alcohol or other solution containing water. However, in some embodiments, the water comprises purified water, such as water from the United States Pharmacopeia (“USP”) or deionized water. For example, when the antipathogenic solvent comprises water, the coating material can comprise any suitable amount of water. In fact, in some embodiments, in addition to silicone oil, the silicone oil solvent, the antipathogenic agent, alcohol and / or any other suitable ingredient, the remainder of the coating material comprises water. In some embodiments, the coating material comprises from approximately 1% to approximately 99% water.
    [030] In some embodiments, the antiseptic coating further comprises at least one additional biocidal agent. In such embodiments, an additional biocidal agent may comprise any suitable chemical reagent or chemical reagents that kill, reduce or otherwise prevent the proliferation of the pathogen while allowing the antiseptic coating material to disinfect and lubricate the surfaces of the intravascular device and is suitable for use on human skin. Some examples of suitable biocidal agents include silver and / or copper ions and nanoparticles (e.g., tinosan silver citrate dihydrogen), silver sulfadiazine, an imidozole, a triazole, an aliamine, phenol, hexachlorophene, an antibiotic and a sulfonamide.
    [031] When the antiseptic coating material comprises an additional biocidal agent, the coating material may comprise any suitable portion of the biocidal agent. In one example, an additional biocidal agent comprises from approximately 0.01% to approximately 10% of the total weight of the coating material. In another example, the biocidal agent comprises from approximately 0.1% to approximately 5% of the coating material, by weight. In yet another example, a biocidal agent
    Petition 870180057384, of 07/03/2018, p. 24/34
    Additional 12/17 comprises from approximately 0.5% to approximately 2% of the antiseptic coating material, by weight.
    [032] In addition to the aforementioned ingredients, the antiseptic coating material can include any suitable ingredient, in any suitable concentration, which allows the coating material to lubricate disinfect the surfaces, which is suitable for use in the dermis and to prevent colonization of pathogens. Some examples of such optional ingredients may include thickening agents, neutralizing agents, pH adjusting agents, metal salts, dyes, fragrances and / or other suitable chemical reagents.
    [033] The antiseptic coating material can also be modified to have any suitable characteristic desired to enable application of the material on a desired surface. For example, in some embodiments, the coating material comprises a liquid that is applied to the surface of an intravenous device by dipping or brushing. In other embodiments, the coating material comprises at least one of a gel, cream, foam, aerosol or other fluid that has a desired consistency / viscosity.
    [034] The antiseptic coating material can be used in any suitable way. For example, the coating material can be arranged on and / or inside a receptacle, from which the material can be supplied or otherwise used to clean an object. In such cases, the coating material can be arranged on and / or within any suitable receptacle with any component, device or feature that allows it to be used with the coating material while allowing the coating material to act as intended. Some examples of suitable receptacles may include an absorbent material (for example, a disposable tissue, a gauze pad, a cotton swab, a swabstick, a sponge, a sponge with a fluid-filled reservoir, a tissue, a block of fibers etc.), a spray bottle, an aerosol dispenser or any other suitable container.
    Petition 870180057384, of 7/3/2018, p. 25/34
    13/17 [035] When the antiseptic coating material is disposed on and / or within an absorbent material, the material can comprise any suitable substance that is capable of absorbing the coating material, releasing part of the material when the absorbent material enters in contact (for example, wipes) with a surface that is suitable for use on human skin. Some examples of suitable substances may comprise cotton, paper, cellulose, wool, polyester, polypropylene, fabric or other material that is capable of forming an absorbent object capable of applying the coating to a surface.
    [036] The coating material can be applied to virtually any surface. In one example, the coating material is applied directly to the skin (for example, to disinfect the hands, to clean a part of a patient's skin before the skin is punctured, to clean and care for a patient's skin after it has been perforated, etc.). In another example, the coating material is applied to objects that are not live, such as medical instruments, floors, chairs, door handles, tables, computer keyboards, computer mouse, etc.
    [037] The coating material can be used to coat a surface in any suitable manner. For example, an object, such as a medical instrument (for example, a catheter, syringe, scalpel or other object used in healthcare settings) can be coated with antiseptic material. In this example, the coating material is applied to the object in any suitable manner, including rubbing (for example, using an absorbent material), spraying, soaking, vaporizing, immersing or otherwise applying the coating material to the object. Additionally, in this example, when an object is coated with the antiseptic material, the coating material provides a lubricating layer of antipathogenic agent that is not easily removed through contact with a patient. Thus, the layer of antipathogenic material may remain on the object for some period of time and, thus, act to prevent the growth of pathogens and reduce the amount of pathogens that
    Petition 870180057384, of 7/3/2018, p. 26/34
    14/17 will colonize the coated surface of the object.
    EXAMPLES [038] The antimicrobial efficacy of formulation 3 (see Table 1, above) was tested using zone of inhibition experiments, as follows. An antiseptic coating material was provided through the miscible combination of chlorhexidine diacetate (0.49%), triclosan (0.49%), USP ethanol (13.85%), dimethylsiloxane and trifluorpropylmethylsiloxane (84.09%) and surfactant polyethoxylated Cremophor EL® (1.09%). The antiseptic coating material was then applied to the outer surface of Becton Dickenson® QSyte ™ catheter components. A first set of coated catheter components was then washed in USP water to remove any unbound coating material and a second set of coated catheter components was not washed. Finally, a third set of uncoated catheter components (control group) was washed separately in USP water.
    [039] Triplicate samples of pathogens P. aeruginosa, S. aureus, E. coli and C. albicans were plated on agarose growth media. One of each sample received a washed coated catheter component, one of each sample received an unwashed coated catheter component and one of each sample received an uncoated control catheter component. The twelve samples were then incubated at 37 ° C for seven days. On each day, the samples were removed from the incubator and the zone of inhibition was measured. The results of the experiment are shown in Tables 2 to 4, below.
    Table 2
    Catheter Component Fully Coated with Formulation 9
    Petition 870180057384, of 7/3/2018, p. 27/34
    15/17
    Ε.
    Agent Pa- p aeruginosa S. aureus coli C. albicans togenic
    Day 1 2mm 19mm 9mm 3 mm Day 2 lmm ISmm 9mm 5mm day 3 Omm 18mm 1mm AT 6th Omm 16mm lmm 5mm day 7 Omm 16mm lmm 5 mm
    Table 3
    Coated Catheter Component Washed with Formulation 9
    AND.
    Pathogen p. aeruginosa S. aureus coli C. albicans
    Day 1 Omm 2mm I 1 mm lmm Day 2 Omm 21mm 1mm lmm day 3 Omm 20mm 1mm AT 6th Omm 18mm 9mm lmm day 7 Omm 18mm 9mm lmm
    Table 4
    Washed Uncoated Catheter Component (control)
    AND.
    Pathogenic Agent E. aeruginosa S. aureus coli C. albicans
    Day 1 Omm Omm Omm Omm Day 2 Omm Omm Omm Omm day 3 Omm Omin Omm AT 6th Omm Omm Omm Omm day 7 Omm Omm Omm Omm
    [040] Table 2 shows the results from samples of agents
    Petition 870180057384, of 7/3/2018, p. 28/34
    16/17 pathogenic containing the catheter components completely coated and not washed. As shown, the antiseptic coating material of formulation 9 demonstrated significant inhibition of S. aureus and E. coliao pathogens over the seven day period. In addition, although C. albicans showed slightly less inhibition than S. aureus and E. coli, P. aeruginosa exhibited significant resistance to the formulation 9.
    [041] Table 3 shows the results from the pathogen samples containing the washed coated catheter components. As shown, the antiseptic coating material of formulation 9 demonstrated significant inhibition of the pathogens S. aureus and E. coli over the seven-day period, despite a pre-wash of the catheter components. Again, the pathogens P. aeruginosa and C. albicans showed little or no inhibition of the coating material after prewash. These results confirm both the cohesive nature of the coating material due to the silicone oil component and the mutual miscibility of the antipathogenic agent with the rest of the coating material components.
    [042] Finally, Table 4 shows the results from pathogenic samples that contain the uncoated catheter components or the control sample. As shown, without the coating material of formulation 9, all samples showed no inhibition. Consequently, the antiseptic coating material of the present invention has proven to be highly efficient in killing or preventing the proliferation of various pathogens that commonly cause infections in the bloodstream.
    [043] The present invention can be incorporated in other specific forms without departing from its structures, methods or other essential characteristics as is widely described here and claimed later here. The modalities and examples described should all be considered under each aspect only as illustrative and not as being restrictive. The scope of the invention is therefore indicated by the appended claims, rather than by the previous description. All changes that fit within the meaning and equivalence range of the claims must be included within their scope.
    Petition 870180057384, of 7/3/2018, p. 29/34
    1/3
    权利要求:
    Claims (12)
    [1]
    1. Antimicrobial composition CHARACTERIZED by the fact that it comprises: an antipathogenic agent;
    a first solvent capable of dissolving the antipathogenic agent, the solvent being selected from the group consisting of water, a C1 alcohol and a C2 alcohol;
    a lubricating agent represented by a silicone oil: and a second solvent capable of dissolving the lubricating agent, in which the first solvent and the second solvent are mutually miscible.
    [2]
    2. Composition according to claim 1, CHARACTERIZED by the fact that the second solvent is at least one of a hydrocarbon, a ketone, a halogenated hydrocarbon and an alcohol having at least 3 carbon atoms.
    [3]
    3. Composition according to claim 1, CHARACTERIZED by the fact that the second solvent is a polyethoxylated surfactant.
    [4]
    4. Composition, according to claim 1, CHARACTERIZED by the fact that the antipathogenic agent is at least one of chlorhexidine diacetate, chlorhexidine gluconate, triclosan, benzalkonium chloride and para-chloro-meta-xylenol (PCMX).
    [5]
    5. Composition according to claim 1, CHARACTERIZED by the fact that the silicone oil is at least one of dimethylsiloxane and trifluorpropylmethylsiloxane.
    [6]
    6. Composition according to claim 2, CHARACTERIZED by the fact that the second solvent comprises two or more hydrocarbons, ketones, halogenated hydrocarbons, alcohols having at least three carbon atoms and combinations of these.
    [7]
    7. Method for producing an antimicrobial composition, as defined in any one of claims 1 to 6, the method CHARACTERIZED by the fact that it comprises:
    select the antipathogenic agent:
    select the first solvent capable of dissolving the antipathogenic agent, the solvent
    Petition 870180057384, of 7/3/2018, p. 31/34
    2/3 being selected from a group consisting of water, a C1 alcohol and a C2 alcohol;
    dissolving the antipathogenic agent in the first solvent to provide a first miscible solution;
    select the lubricating agent represented by a silicone oil; selecting the second solvent capable of dissolving the lubricating agent; dissolving the lubricating agent in the second solvent to provide a second miscible solution; and mix the first and second miscible solutions homogeneously.
    [8]
    8. Intravascular system for the prevention of catheter-related bloodstream infections, the system CHARACTERIZED by the fact that it comprises:
    a vascular access device that has an external surface; and an antiseptic coating applied to the outer surface, the antiseptic coating including:
    an antipathogenic agent;
    a first solvent capable of dissolving the antipathogenic agent, the solvent being selected from the group consisting of water, a C1 alcohol and a C2 alcohol;
    a lubricating agent represented by a silicone oil; and a second solvent capable of dissolving the lubricating agent, wherein the first solvent and the second solvent are mutually miscible.
    [9]
    9. System according to claim 8, CHARACTERIZED by the fact that the vascular access device additionally comprises a syringe.
    [10]
    10. System according to claim 8, CHARACTERIZED by the fact that the second solvent is at least one of a hydrocarbon, a ketone, a halogenated hydrocarbon and an alcohol that have at least 3 carbon atoms.
    [11]
    11. System, according to claim 8, CHARACTERIZED by the fact that the second solvent is a polyethoxylated surfactant.
    Petition 870180057384, of 7/3/2018, p. 32/34
    3/3
    [12]
    12. System according to claim 8, CHARACTERIZED by the fact that the silicone oil is at least one of dimethylsiloxane and trifluorpropylmethylsiloxane.
    Petition 870180057384, of 7/3/2018, p. 33/34
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012005874B1|2018-10-09|antimicrobial composition, method for producing an antimicrobial composition and intravascular system for the prevention of catheter-related bloodstream infections
    JP6557283B2|2019-08-07|Intravenous medical equipment
    AU2009335672B2|2015-05-07|Chlorhexidine acetate antiseptic cleaning agent
    US8343525B2|2013-01-01|Chlorhexidine acetate antiseptic cleaning agent
    AU2012346043B2|2016-09-29|Antimicrobial composition including a residual barrier film
    JP5998051B2|2016-09-28|Antibacterial coating for invasive devices through the skin
    EP1085921A2|2001-03-28|Antimicrobial alcohol gel pre-operative skin-preparation delivery systems
    Echols et al.2015|Role of antiseptics in the prevention of surgical site infections
    JP6803382B2|2020-12-23|Antibacterial composition for surgical use
    JP3996215B2|2007-10-24|Disinfecting composition
    同族专利:
    公开号 | 公开日
    EP2477670B1|2016-11-23|
    ES2615493T3|2017-06-07|
    US20110065798A1|2011-03-17|
    JP2013505062A|2013-02-14|
    BR112012005874A2|2016-02-16|
    JP5868323B2|2016-02-24|
    EP2477670A2|2012-07-25|
    AU2010295926B2|2015-02-12|
    WO2011034675A2|2011-03-24|
    US20150079144A1|2015-03-19|
    IN2012DN02024A|2015-07-31|
    AU2010295926A1|2012-03-22|
    CN102497894A|2012-06-13|
    WO2011034675A3|2011-05-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3223629A|1963-05-13|1965-12-14|Shell Oil Co|Lubricant compositions|
    US4339336A|1981-03-23|1982-07-13|Texaco Inc.|Quaternary ammonium succinimide salt composition and lubricating oil containing same|
    US4677143A|1984-10-01|1987-06-30|Baxter Travenol Laboratories, Inc.|Antimicrobial compositions|
    US4603152A|1982-11-05|1986-07-29|Baxter Travenol Laboratories, Inc.|Antimicrobial compositions|
    US4716032A|1983-08-03|1987-12-29|Geoffrey J. Westfall|Aerosol spray composition for mastitis prevention|
    WO1985001876A1|1983-10-24|1985-05-09|Lockley Services Pty. Ltd.|Foamable biocide composition|
    US4584192A|1984-06-04|1986-04-22|Minnesota Mining & Manufacturing Company|Film-forming composition containing an antimicrobial agent and methods of use|
    CA1245931A|1984-09-21|1988-12-06|Sophia Pesotchinsky|Positionable tissue interfacing device for themanagement of percutaneous conduits|
    DE3502594A1|1985-01-26|1986-07-31|Etablissement Dentaire Ivoclar, Schaan|X-RAY OPAQUE DENTAL MATERIAL|
    US4642126A|1985-02-11|1987-02-10|Norton Company|Coated abrasives with rapidly curable adhesives and controllable curvature|
    US4629743A|1985-05-20|1986-12-16|The B.F. Goodrich Company|Process for preparing high bulk density vinyl resins|
    KR900006272B1|1985-07-24|1990-08-27|마쯔시다덴기산교 가부시기가이샤|Thermal dye transfer printing systems thermal printing sheets and dye receiving sheet|
    US4955890A|1986-01-16|1990-09-11|Vitaphore Corporation|Surgical skin incision device, percutaneous infection control kit and methods of use|
    IL78826A|1986-05-19|1991-05-12|Yissum Res Dev Co|Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom|
    US4895566A|1986-07-25|1990-01-23|C. R. Bard, Inc.|Coating medical devices with cationic antibiotics|
    US6051609A|1997-09-09|2000-04-18|Tristrata Technology, Inc.|Additives enhancing the effect of therapeutic agents|
    US4798594A|1987-09-21|1989-01-17|Cordis Corporation|Medical instrument valve|
    US5019096A|1988-02-11|1991-05-28|Trustees Of Columbia University In The City Of New York|Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same|
    US4999210A|1989-01-18|1991-03-12|Becton, Dickinson And Company|Anti-infective and antithrombogenic medical articles and method for their preparation|
    US4925668A|1989-01-18|1990-05-15|Becton, Dickinson And Company|Anti-infective and lubricious medical articles and method for their preparation|
    US5266359A|1991-01-14|1993-11-30|Becton, Dickinson And Company|Lubricative coating composition, article and assembly containing same and method thereof|
    US5773487A|1991-05-15|1998-06-30|Uv Coatings, Inc.|Finishing composition which is curable by UV light and method of using same|
    CA2125167A1|1991-12-06|1993-06-10|North Shore University Hospital Research Corporation|Method of reducing medical device related infections|
    US5217493A|1992-03-11|1993-06-08|Board Of Regents, The University Of Texas System|Antibacterial coated medical implants|
    TW227518B|1992-06-30|1994-08-01|Toa Gosei Chem Ind|
    DE4312656C2|1993-04-19|1996-01-25|Beiersdorf Ag|Cooling cosmetic or dermatological compositions|
    US5352378A|1993-05-27|1994-10-04|Minnesota Mining And Manufacturing Company|Nonflammable lubricious composition|
    JPH0751651A|1993-08-19|1995-02-28|Mitsubishi Materials Corp|Coating material for dirt prevention and deodorization|
    US5547662A|1993-08-27|1996-08-20|Becton, Dickinson And Company|Preparation of a skin surface for a surgical procedure|
    US5512199A|1993-11-02|1996-04-30|Becton Dickinson And Company|Hand wipe solution|
    US5540661A|1994-05-03|1996-07-30|Medex, Inc.|Needleless valve having a covalently bonded lubricious coating|
    CA2154112C|1994-08-22|2000-09-26|Mohammad A. Khan|Water soluble lubricant for medical devices|
    US5688747A|1994-08-22|1997-11-18|Becton Dickinson And Company|Water based lubricant solution|
    US6413539B1|1996-10-31|2002-07-02|Poly-Med, Inc.|Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof|
    GB9516658D0|1995-08-15|1995-10-18|Smiths Industries Plc|Medico-surgical devices|
    US6503952B2|1995-11-13|2003-01-07|The Trustees Of Columbia University In The City Of New York|Triple antimicrobial composition|
    SG60166A1|1996-12-09|1999-02-22|Becton Dickinson Co|Waterborne lubricant for teflon products|
    EP0778337A3|1995-12-07|1997-06-25|Becton, Dickinson and Company|Waterborne lubricant for teflon products|
    US5772640A|1996-01-05|1998-06-30|The Trustees Of Columbia University Of The City Of New York|Triclosan-containing medical devices|
    US6120784A|1996-02-20|2000-09-19|Viro-Kote, Inc.|Anti-bacterial/anti-viral coatings, coating process and parameters thereof|
    US6576633B1|1996-02-22|2003-06-10|The Dow Chemical Company|Stable liquid antimicrobial suspension compositions containing quarternaries prepared from hexamethylenetetramine and certain halohydrocarbons|
    CN1187598A|1996-12-09|1998-07-15|贝克顿迪金森公司|Waterborne lubricant for teflon products|
    EP0860213A3|1997-01-03|2002-10-16|Therapol SA|Bioactive coating on surfaces|
    US6242526B1|1997-01-28|2001-06-05|Stepan Company|Antimicrobial polymer latexes derived from unsaturated quaternary ammonium compounds and antimicrobial coatings, sealants, adhesives and elastomers produced from such latexes|
    US6084005A|1997-02-24|2000-07-04|Kuraray Co., Ltd.|Antimicrobial caries-detecting composition|
    US5763412A|1997-04-08|1998-06-09|Becton Dickinson And Company|Film-forming composition containing chlorhexidine gluconate|
    US8187278B2|1998-08-25|2012-05-29|Advanced Photodynamic Technologies, Inc.|Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and benzalkonium chloride|
    US6153187A|1997-09-02|2000-11-28|Insight Strategy & Marketing Ltd.|Use of glycosaminoglycans degrading enzymes for management of airway associated diseases|
    US6830745B1|1997-10-16|2004-12-14|Pharmacal Biotechnologies, Llc|Compositions for treating biofilm|
    US20020037260A1|1997-10-16|2002-03-28|Budny John A.|Compositions for treating biofilm|
    EP1023036B1|1997-10-18|2002-01-09|DDG Dental Devices GmbH|Disinfecting agent|
    US6127320A|1998-01-19|2000-10-03|University Of Cincinnati|Methods and compositions for increasing lubricity of rubber surfaces|
    WO1999042080A2|1998-02-19|1999-08-26|Oraceutical, Llc|Curable compositions with antimicrobial properties|
    US6726899B2|1998-09-24|2004-04-27|Advantage Dental Products, Inc.|Calcified tissue facing preparation containing antimicrobial agent|
    AU2042200A|1998-12-07|2000-06-26|Baylor College Of Medicine|Preventing and removing biofilm from the surface of medical devices|
    US6221097B1|1999-03-22|2001-04-24|Scimed Life System, Inc.|Lubricated sleeve material for stent delivery|
    US6224579B1|1999-03-31|2001-05-01|The Trustees Of Columbia University In The City Of New York|Triclosan and silver compound containing medical devices|
    US6706022B1|1999-07-27|2004-03-16|Alaris Medical Systems, Inc.|Needleless medical connector with expandable valve mechanism|
    US7384895B2|1999-08-16|2008-06-10|Ecolab Inc.|Conveyor lubricant, passivation of a thermoplastic container to stress cracking and thermoplastic stress crack inhibitor|
    US6326417B1|1999-10-21|2001-12-04|Jeneric/Pentron Incorporated|Anti-microbial dental compositions and method|
    US6353041B1|1999-10-22|2002-03-05|Kerr Corporation|Dental compositions|
    US6310013B1|1999-10-27|2001-10-30|Ecolab Inc.|Lubricant compositions having antimicrobial properties and methods for manufacturing and using lubricant compositions having antimicrobial properties|
    AUPQ419099A0|1999-11-23|1999-12-16|Ko, Thomas Sai Ying|Novel compositions and methods|
    AT253082T|1999-12-08|2003-11-15|Ciba Sc Holding Ag|NEW PHOTOINITIATOR SYSTEM MADE OF PHOSPHINOXIDE COMPOUNDS AND LITTLE COLORED CURABLE COMPOSITIONS|
    US6579539B2|1999-12-22|2003-06-17|C. R. Bard, Inc.|Dual mode antimicrobial compositions|
    CA2395610A1|1999-12-30|2001-07-12|University Of Louisville Research Foundation, Inc.|Methods and compositions for inhibiting adhesion by microorganisms|
    AT548016T|2000-04-03|2012-03-15|Chx Technologies Inc|USE OF CHLORHEXIDINE FOR THE PREVENTION OF ROOT CARIES|
    AUPQ681200A0|2000-04-10|2000-05-11|Unisearch Limited|Antimicrobial coatings|
    US6861060B1|2000-04-21|2005-03-01|Elena Luriya|Personal care formulations|
    US6559176B1|2000-05-10|2003-05-06|Princeton University|Compounds and methods for regulating bacterial growth and pathogenesis|
    DE60137334D1|2000-06-09|2009-02-26|Baylor College Medicine|Combination of Antimicrobial Agents and Bacterial Interference for Transferring Medical Devices|
    EP1164171A3|2000-06-12|2002-04-24|General Electric Company|Silicone compositions|
    WO2001098214A1|2000-06-19|2001-12-27|Novozymes Biotech, Inc.|Methods for eliminating the formation of biofilm|
    CN1206911C|2000-10-12|2005-06-22|凌沛学|Compound biocide composite|
    US7329412B2|2000-12-22|2008-02-12|The Trustees Of Columbia University In The City Of New York|Antimicrobial medical devices containing chlorhexidine free base and salt|
    US6814085B2|2000-12-29|2004-11-09|Steven J. Brattesani|Dental floss with usage identification capability|
    FR2823113B1|2001-04-06|2005-12-16|Oreal|ANTI-WRINKLE COSMETIC COMPOSITION WITH IMMEDIATE EFFECT BASED ON AQUEOUS DISPERSION OF AT LEAST ONE MINERAL LOAD|
    WO2002085386A2|2001-04-23|2002-10-31|Nucryst Pharmaceuticals Corp.|Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue|
    JP4116447B2|2001-05-01|2008-07-09|エイ．ブイ．トップチーブインスティテュートオブペトロケミカルシンセシス|Hydrogel composition|
    FR2826292B1|2001-06-22|2004-01-23|Rhodia Chimie Sa|OIL-IN-OIL EMULSIONS COMPRISING A SILICONE, DISPERSIONS OF SUCH EMULSIONS AND USE THEREOF|
    ITMI20011411A1|2001-07-04|2003-01-07|Lafabrica S R L|METHOD TO PROTECT A MATERIAL FOR FLOORING OR COATING FROM MACHINING SUBSTANCES|
    WO2003011821A2|2001-07-31|2003-02-13|Board Of Regents The University Of Texas System|Use of cyclic heptapeptides for the inhibition of biofilm formation|
    DE10139574A1|2001-08-10|2003-02-20|Creavis Tech & Innovation Gmbh|Maintaining the lotus effect by preventing microbial growth on self-cleaning surfaces|
    US6846846B2|2001-10-23|2005-01-25|The Trustees Of Columbia University In The City Of New York|Gentle-acting skin disinfectants|
    WO2003039529A1|2001-11-07|2003-05-15|4Sc A.G.|Selective antibacterial agents|
    BR0307066A|2002-01-22|2004-12-28|Upjohn Co|Infection Resistant Medical Device|
    US20030144362A1|2002-01-28|2003-07-31|Utterberg David S.|High viscosity antibacterials for cannulae|
    US7361719B2|2002-01-31|2008-04-22|Micro Science Tech Co., Ltd.|Monomer with anti-microbial character, polymer using the same, and manufacturing method thereof|
    US6887270B2|2002-02-08|2005-05-03|Boston Scientific Scimed, Inc.|Implantable or insertable medical device resistant to microbial growth and biofilm formation|
    DE60321773D1|2002-03-14|2008-08-07|Ash Access Technology Inc|MEDICAL DEVICES WITH ANTIBACTERIAL PROPERTIES|
    CA2476288A1|2002-03-26|2003-10-09|Biosynexus Incorporated|Enzyme disruption of bacterial biofilms|
    AU2003225073A1|2002-04-18|2003-11-03|The University Of Iowa Research Foundation|Methods of inhibiting and treating bacterial biofilms by metal chelators|
    US20040115477A1|2002-12-12|2004-06-17|Bruce Nesbitt|Coating reinforcing underlayment and method of manufacturing same|
    US7195615B2|2003-05-14|2007-03-27|Boston Scientific Scimed, Inc.|System for providing a medical device with anti-microbial properties|
    DK1644024T3|2003-06-06|2019-10-07|Univ Texas|ANTIMICROBIAL RINSE SOLUTIONS|
    US8454566B2|2003-07-10|2013-06-04|Medtronic Minimed, Inc.|Methods and compositions for the inhibition of biofilms on medical devices|
    US8043632B2|2003-08-18|2011-10-25|E. I. Du Pont De Nemours And Company|Process for making antimicrobial articles by reacting chitosan with amino-reactive polymer surfaces|
    US20050048005A1|2003-08-26|2005-03-03|Stockel Richard F.|Antimicrobial compositions for dental applications|
    US7381751B2|2003-08-26|2008-06-03|Shantha Sarangapani|Antimicrobial composition for medical articles|
    US20050059731A1|2003-09-16|2005-03-17|Ceramoptec Industries, Inc.|Erythrosin-based antimicrobial photodynamic therapy compound and its use|
    WO2005037338A1|2003-10-14|2005-04-28|Cook Incorporated|Hydrophilic coated medical device|
    AU2006223137A1|2005-03-10|2006-09-21|3M Innovative Properties Company|Methods of reducing microbial contamination|
    US7318937B2|2005-03-18|2008-01-15|Closure Medical Corporation|Liquid coating compositions|
    US20070005064A1|2005-06-27|2007-01-04|Sdgi Holdings|Intervertebral prosthetic device for spinal stabilization and method of implanting same|
    DE102005040211B4|2005-08-16|2010-02-11|Maquet Cardiopulmonary Ag|Use of nonionic esters in a coating for blood contacting surfaces and medical device|
    US20100113871A1|2006-09-13|2010-05-06|Aylvin Jorge Angelo Athanasius Dias|Antimicrobial coating|
    EP2117494A4|2007-01-29|2012-03-28|Bisco Inc|Dental primer adhesive system and optional hydrophobic resin|
    EP2011831B1|2007-07-03|2013-10-23|Shin-Etsu Chemical Co., Ltd.|Coating composition and a coating therefrom having waterdrop sliding property|
    US8821455B2|2009-07-09|2014-09-02|Becton, Dickinson And Company|Antimicrobial coating for dermally invasive devices|US20100135949A1|2008-12-01|2010-06-03|Becton, Dickinson And Company|Antimicrobial compositions|
    US9545360B2|2009-05-13|2017-01-17|Sio2 Medical Products, Inc.|Saccharide protective coating for pharmaceutical package|
    US9458536B2|2009-07-02|2016-10-04|Sio2 Medical Products, Inc.|PECVD coating methods for capped syringes, cartridges and other articles|
    PL2251454T3|2009-05-13|2014-12-31|Sio2 Medical Products Inc|Vessel coating and inspection|
    US8821455B2|2009-07-09|2014-09-02|Becton, Dickinson And Company|Antimicrobial coating for dermally invasive devices|
    US9878101B2|2010-11-12|2018-01-30|Sio2 Medical Products, Inc.|Cyclic olefin polymer vessels and vessel coating methods|
    US9272095B2|2011-04-01|2016-03-01|Sio2 Medical Products, Inc.|Vessels, contact surfaces, and coating and inspection apparatus and methods|
    US11116695B2|2011-11-11|2021-09-14|Sio2 Medical Products, Inc.|Blood sample collection tube|
    EP2776603B1|2011-11-11|2019-03-06|SiO2 Medical Products, Inc.|PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS|
    US20130255061A1|2012-04-03|2013-10-03|Becton, Dickinson And Company|Systems and methods for applying a novel antimicrobial coating material to a medical device|
    SE537334C2|2012-04-27|2015-04-07|Vigmed Ab|Protective device for needle point and mounting device|
    US9352119B2|2012-05-15|2016-05-31|Becton, Dickinson And Company|Blood control IV catheter with antimicrobial properties|
    US9579486B2|2012-08-22|2017-02-28|Becton, Dickinson And Company|Blood control IV catheter with antimicrobial properties|
    EP2888317B1|2012-08-24|2019-03-06|Citrox Biosciences Limited|Bioflavonoid coated materials|
    JP6509734B2|2012-11-01|2019-05-08|エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド|Film inspection method|
    WO2014078666A1|2012-11-16|2014-05-22|Sio2 Medical Products, Inc.|Method and apparatus for detecting rapid barrier coating integrity characteristics|
    CN105705676B|2012-11-30|2018-09-07|Sio2医药产品公司|Control the uniformity of the PECVD depositions on injector for medical purpose, cylindrantherae etc.|
    US9764093B2|2012-11-30|2017-09-19|Sio2 Medical Products, Inc.|Controlling the uniformity of PECVD deposition|
    US9695323B2|2013-02-13|2017-07-04|Becton, Dickinson And Company|UV curable solventless antimicrobial compositions|
    US9750928B2|2013-02-13|2017-09-05|Becton, Dickinson And Company|Blood control IV catheter with stationary septum activator|
    US20160015898A1|2013-03-01|2016-01-21|Sio2 Medical Products, Inc.|Plasma or cvd pre-treatment for lubricated pharmaceutical package, coating process and apparatus|
    KR102167557B1|2013-03-11|2020-10-20|에스아이오2 메디컬 프로덕츠, 인크.|Coated Packaging|
    US9937099B2|2013-03-11|2018-04-10|Sio2 Medical Products, Inc.|Trilayer coated pharmaceutical packaging with low oxygen transmission rate|
    US9750927B2|2013-03-11|2017-09-05|Becton, Dickinson And Company|Blood control catheter with antimicrobial needle lube|
    US9327095B2|2013-03-11|2016-05-03|Becton, Dickinson And Company|Blood control catheter with antimicrobial needle lube|
    WO2014144926A1|2013-03-15|2014-09-18|Sio2 Medical Products, Inc.|Coating method|
    EP3693493A1|2014-03-28|2020-08-12|SiO2 Medical Products, Inc.|Antistatic coatings for plastic vessels|
    US10376686B2|2014-04-23|2019-08-13|Becton, Dickinson And Company|Antimicrobial caps for medical connectors|
    US9675793B2|2014-04-23|2017-06-13|Becton, Dickinson And Company|Catheter tubing with extraluminal antimicrobial coating|
    US9789279B2|2014-04-23|2017-10-17|Becton, Dickinson And Company|Antimicrobial obturator for use with vascular access devices|
    US10232088B2|2014-07-08|2019-03-19|Becton, Dickinson And Company|Antimicrobial coating forming kink resistant feature on a vascular access device|
    US20160287794A1|2015-04-02|2016-10-06|Xend Medical Systems, Llc|Hypodermic needle system activation mechanism|
    KR20180048694A|2015-08-18|2018-05-10|에스아이오2 메디컬 프로덕츠, 인크.|Packaging containers for medicines and other products with low oxygen transfer rates|
    US10493244B2|2015-10-28|2019-12-03|Becton, Dickinson And Company|Extension tubing strain relief|
    US9474768B1|2016-05-18|2016-10-25|Reoxcyn Discoveries Group, Inc.|Lubricant formulations|
    CN106039423A|2016-06-02|2016-10-26|江苏吉春医用器材有限公司|Silicification liquid for injector needle tip|
    LT3484535T|2016-07-14|2022-02-10|Hollister Incorporated|Hygienic medical devices having hydrophilic coating and methods of forming the same|
    WO2018175529A1|2017-03-21|2018-09-27|Velano Vascular, Inc.|Systems and methods for controlling catheter device size|
    CN108553693A|2018-05-17|2018-09-21|江汉大学|The preparation method of resisting gram-positive bacteria coating and medical instrument comprising coating|
    CN111303980A|2020-03-06|2020-06-19|吉林云飞医药有限公司|Lubricating oil and preparation method and application thereof|
    法律状态:
    2018-04-03| B07A| Technical examination (opinion): publication of technical examination (opinion)|
    2018-09-11| B09A| Decision: intention to grant|
    2018-10-09| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/08/2010, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    US12/561,863|US20110065798A1|2009-09-17|2009-09-17|Anti-infective lubricant for medical devices and methods for preparing the same|
    PCT/US2010/045616|WO2011034675A2|2009-09-17|2010-08-16|Anti-infective lubricant for medical devices and methods for preparing the same|
    [返回顶部]